Literature DB >> 15504338

Expression and characterization of the first kunitz domain of human tissue factor pathway inhibitor-2.

Desheng Kong1, Duan Ma, Hao Bai, Hongshen Guo, Xu Cai, Wei Mo, Qiqun Tang, Houyan Song.   

Abstract

Human tissue factor pathway inhibitor-2 (hTFPI-2) has three kunitz domains whose structure and function are unclear. We expressed the first kunitz domain of hTFPI-2 (hTFPI-2/KD1) as functional form using Pichia pastoris and investigated its characterization. In the experiment, hTFPI-2/KD1 can inhibit the plasmin and trypsin activity and the Ki of hTFPI-2/KD1 towards plasmin (30nM) and trypsin (50nM) was determined as 10 and 7nM by chromogenic assay, respectively. hTFPI-2/KD1 can also inhibit MMP-2 and MMP-9 in zymography assay. Furthermore, the inhibition of hTFPI-2/KD1 to the Matrigel invasion by HT-1080 is also described. This study provides a method to produce hTFPI-2/KD1 efficiently and some insights into the structure and function of hTFPI-2/KD1.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15504338     DOI： 10.1016/j.bbrc.2004.09.179

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN： 0006-291X            Impact factor:   3.575


  11 in total

Review 1.  Recent advances in the discovery and development of factor XI/XIa inhibitors.

Authors:  Rami A Al-Horani; Daniel K Afosah
Journal:  Med Res Rev       Date:  2018-05-04       Impact factor: 12.944

2.  Protective effects of recombinant kunitz-domain 1 of human tissue factor pathway inhibitor-2 against 2-chloroethyl ethyl sulfide toxicity in vitro.

Authors:  Moonsuk S Choi; Kalpana Parikh; Ashima Saxena; Nageswararao Chilukuri
Journal:  Eplasty       Date:  2007-12-03

3.  Transient RNA silencing of tissue factor pathway inhibitor-2 modulates lung cancer cell invasion.

Authors:  Sophie Iochmann; Claire Bléchet; Valérie Chabot; Annabelle Saulnier; Aniça Amini; Guillaume Gaud; Yves Gruel; Pascale Reverdiau
Journal:  Clin Exp Metastasis       Date:  2009-03-07       Impact factor: 5.150

4.  The TFPI-2 derived peptide EDC34 improves outcome of gram-negative sepsis.

Authors:  Praveen Papareddy; Martina Kalle; Ole E Sørensen; Martin Malmsten; Matthias Mörgelin; Artur Schmidtchen
Journal:  PLoS Pathog       Date:  2013-12-05       Impact factor: 6.823

5.  Human tissue factor pathway inhibitor-2 suppresses the wound-healing activities of human Tenon's capsule fibroblasts in vitro.

Authors:  Yuan Jing; Yu Jian-Xiong
Journal:  Mol Vis       Date:  2009-11-12       Impact factor: 2.367

Review 6.  Recent advances on plasmin inhibitors for the treatment of fibrinolysis-related disorders.

Authors:  Rami A Al-Horani; Umesh R Desai
Journal:  Med Res Rev       Date:  2014-03-21       Impact factor: 12.944

7.  Low expression of TFPI-2 associated with poor survival outcome in patients with breast cancer.

Authors:  Cheng Xu; Huijun Wang; Hongyu He; Fengyun Zheng; Yating Chen; Jin Zhang; Xiaoyan Lin; Duan Ma; Hongwei Zhang
Journal:  BMC Cancer       Date:  2013-03-15       Impact factor: 4.430

8.  Tissue factor pathway inhibitor 2 is found in skin and its C-terminal region encodes for antibacterial activity.

Authors:  Praveen Papareddy; Martina Kalle; Ole E Sørensen; Katarina Lundqvist; Matthias Mörgelin; Martin Malmsten; Artur Schmidtchen
Journal:  PLoS One       Date:  2012-12-26       Impact factor: 3.240

9.  Tissue factor pathway inhibitor-2 was repressed by CpG hypermethylation through inhibition of KLF6 binding in highly invasive breast cancer cells.

Authors:  Hongshen Guo; Yifeng Lin; Hongwei Zhang; Juan Liu; Nong Zhang; Yiming Li; Desheng Kong; Qiqun Tang; Duan Ma
Journal:  BMC Mol Biol       Date:  2007-12-03       Impact factor: 2.946

10.  Protective effects of recombinant kunitz-domain 1 of human tissue factor pathway inhibitor-2 against 2-chloroethyl ethyl sulfide toxicity in vitro.

Authors:  Moonsuk S Choi; Kalpana Parikh; Ashima Saxena; Nageswararao Chilukuri
Journal:  J Burns Wounds       Date:  2007-07-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.